• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review - Product Image

Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review

  • Published: May 2014
  • 43 pages
  • GlobalData

FEATURED COMPANIES

  • Alkermes, Inc.
  • Ambrx, Inc.
  • ANDRX Corporation
  • Depomed, Inc.
  • DURECT Corporation
  • Nektar Therapeutics
  • MORE

Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – READ MORE >

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
Flamel Technologies S.A. - Key Facts
Flamel Technologies S.A. - Key Employees
Flamel Technologies S.A. - Key Employee Biographies
Flamel Technologies S.A. - Major Products and Services
Flamel Technologies S.A. - Pharmaceutical Pipeline Products Data
Flamel Technologies S.A., Pipeline Products by Therapy Area
Flamel Technologies S.A., Pipeline Products by Development Phase
Flamel Technologies S.A. - History
Flamel Technologies S.A. - Company Statement
Flamel Technologies S.A. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Flamel Technologies S.A. - Key Manufacturing Facilities
Section 2 – Company Analysis
Flamel Technologies S.A. - Business Description
Flamel Technologies S.A. - SWOT Analysis
SWOT Analysis - Overview
Flamel Technologies S.A. - Strengths
Strength - Coreg CR-Lead product
Strength - Unique Polymer-Based Drug Delivery Platforms
Strength - Successful Integration of Eclat Pharmaceuticals LLC
Flamel Technologies S.A. - Weaknesses
Weakness - Declining Profitability
Weakness - Complete Response Letter
Weakness - Dependence on Limited Customer Base
Flamel Technologies S.A. - Opportunities
Opportunity - Need for Novel Delivery Systems
Opportunity - New product Launches
Opportunity - Potential Market for Cardiovascular Drugs
Flamel Technologies S.A. - Threats
Threat - Increasing Parallel Trade
Threat - Uncertain R&D Outcomes
Threat - Intense Competition
Flamel Technologies S.A. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Flamel Technologies S.A., Recent Deals Summary
Section 5 – Company’s Recent Developments
Flamel Technologies S.A., Recent Developments
Apr 29, 2014: Flamel Technologies Announces Receipt of Complete Response Letter From FDA Citing Issues at the Facility of the Supplier of the Active Ingredient
Oct 31, 2013: Flamel Technologies Announces Third Quarter 2013 Results
Oct 17, 2013: Flamel Technologies Announces Projected Release Date of Third Quarter 2013 Results and Conference Call
Sep 11, 2013: Flamel Technologies Announces Acceptance of FDA Review for Second NDA
Jul 29, 2013: Flamel Technologies Announces Second Quarter 2013 Results
Jul 01, 2013: Flamel Technologies Announces Resubmission of Second NDA
Jun 24, 2013: Flamel Technologies Announces Results of 2013 Annual Meeting
May 07, 2013: Flamel Technologies Reports Revenue Of $5.1m In Q1 2013
Mar 22, 2013: US District Court Dismisses Class Action Case Against Flamel Technologies
Feb 28, 2013: Flamel Technologies Reports Revenue Of $26.1m In 2012
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Flamel Technologies S.A., Key Facts
Flamel Technologies S.A., Key Employees
Flamel Technologies S.A., Key Employee Biographies
Flamel Technologies S.A., Major Products and Services
Flamel Technologies S.A., Number of Pipeline Products by Therapy Area
Flamel Technologies S.A., Number of Pipeline Products by Development Stage
Flamel Technologies S.A., Pipeline Products By Therapy Area and Development Phase
Flamel Technologies S.A., History
Flamel Technologies S.A., Subsidiaries
Flamel Technologies S.A., Key Manufacturing Facilities
Flamel Technologies S.A., Key Competitors
Flamel Technologies S.A., Ratios based on current share price
Flamel Technologies S.A., Annual Ratios
Flamel Technologies S.A., Interim Ratios
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Flamel Technologies S.A., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Flamel Technologies S.A., Pipeline Products by Therapy Area
Flamel Technologies S.A., Pipeline Products by Development Phase
Flamel Technologies S.A., Performance Chart (2008 - 2012)
Flamel Technologies S.A., Ratio Charts
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014

Enzon Pharmaceuticals, Inc.
ANDRX Corporation
Ambrx, Inc.
DURECT Corporation
Nektar Therapeutics
Human Genome Sciences, Inc.
Depomed, Inc.
SkyePharma PLC
Alkermes, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos